NCT02537418 2026-03-27
Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens
Canadian Cancer Trials Group
Phase 1 Active not recruiting
Canadian Cancer Trials Group
Gilead Sciences
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Taizhou Mabtech Pharmaceutical Co.,Ltd
R-Pharm
University of Wisconsin, Madison
AstraZeneca
Sigma-Tau Research, Inc.